Symbol="VRNA"
AssetType="Common Stock"
Name="Verona Pharma PLC ADR"
Description="Verona Pharma plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company is headquartered in London, the United Kingdom."
CIK="1657312"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="3 MORE LONDON RIVERSIDE, LONDON, GB"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="1569303000"
EBITDA="-58417000"
PERatio="None"
PEGRatio="0"
BookValue="3.436"
DividendPerShare="0"
DividendYield="0"
EPS="-0.89"
RevenuePerShareTTM="0.006"
ProfitMargin="0"
OperatingMarginTTM="-128.91"
ReturnOnAssetsTTM="-0.161"
ReturnOnEquityTTM="-0.269"
RevenueTTM="458000"
GrossProfitTTM="112000"
DilutedEPSTTM="-0.89"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="32.71"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="18.56"
PriceToBookRatio="4.136"
EVToRevenue="20.96"
EVToEBITDA="-9.4"
Beta="0.18"
num_52WeekHigh="26.44"
num_52WeekLow="8.41"
num_50DayMovingAverage="21.03"
num_200DayMovingAverage="19.43"
SharesOutstanding="79458000"
DividendDate="None"
ExDividendDate="None"
symbol="VRNA"
open="19.06"
high="19.42"
low="18.17"
price="18.25"
volume="704908.00"
latest_trading_day="2023-08-08"
previous_close="19.04"
change="-0.79"
change_percent="-4.1492%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="61"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="39"
Volume_recent_avg="457468"
Change_recent_avg="-0.01"
Delta_recent_avg="0.99"
Variance_recent_avg="0.49"
Change_ratio_recent_avg="-0.08"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="39"
Aroon_momentum_negative="61"
image_negative_thumbnail_id_1="167"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0009.jpeg"
image_negative_thumbnail_id_2="1125"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0158.jpeg"
image_neutral_thumbnail_id_1="581"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0018.jpeg"
image_neutral_thumbnail_id_2="563"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0036.jpeg"
image_positive_thumbnail_id_1="600"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0108.jpeg"
image_positive_thumbnail_id_2="1003"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0165.jpeg"
image_professor_thumbnail_id_1="1181"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0015.jpeg"
image_professor_thumbnail_id_2="1193"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0027.jpeg"
